Key facts
- Hooke Bio’s last known valuation is $7.2M (Sep 2023).
- It has raised $3.8M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Enterprise Ireland, European Innovation Council, Western Development Commission, Davycrest Nominees, University of Limerick Foundation — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Hooke Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Hooke Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hooke Bio
Developer of drug screening technologies designed to test and optimize new microfluidic technology. The company's technology allows pharma companies and clinicians to develop more accurate and responsive disease models for drug testing and to expand the testing of existing therapies on individual patients' disease samples, enabling medical professionals to treat and cure their patients better.
- Sector
- Healthcare
- HQ
- Shannon, Ireland
- Founded
- 2014
- Employees
- 17
- Website
- hookebio.com/
- Ownership
- Privately Held (backing)
Hooke Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hooke Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hooke Bio in its N-PORT filings yet. We sweep new filings monthly.